Nautilus and Abcam Announce Strategic Partnership to Accelerate Exploration of the Proteome
SEATTLE and CAMBRIDGE, England, Nov. 2, 2021 /PRNewswire/ -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or "Nautilus"), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, and Abcam (AIM:ABC; NASDAQ:ABCM), a global innovator in life sciences research tools, today announced a strategic development and supply partnership. The relationship leverages Abcam's...
GenScript Expands Commercial Production in U.S. with State-of-the-Art Gene Synthesis Center
PISCATAWAY, New Jersey, Nov. 2, 2021 /PRNewswire/ -- GenScript USA Inc., the world's leading life science research tools and services provider, announced today that it has opened a larger than 50,000-square-foot facility for highly automated gene synthesis and plasmid preparation services near its U.S. headquarters in Piscataway, New Jersey. The state-of-the-art site marks a significant...
Diabetes is “a pandemic of unprecedented magnitude” now affecting one in 10 adults worldwide, reveals the International Diabetes Federation
New figures from the International Diabetes Federation reveal that 537 million adults around the globe are living with diabetes BRUSSELS, Nov. 2, 2021 /PRNewswire/ -- The International Diabetes Federation (IDF) has released new figures showing that 537 million adults are now living with diabetes worldwide — a rise of 16% (74 million) since the previous IDF estimates in 2019....
Winner Medical to Showcase Innovations in Wound Care and Infection Prevention at MEDICA 2021
SHENZHEN, China, Nov. 2, 2021 /PRNewswire/ -- Winner Medical (300888.SZ), a leading manufacturer for disposable wound care and surgical products, is set to showcase its full set of advanced solutions for wound care and O.R. infection prevention at MEDICA 2021 which is slated to run from November 15-18 in Düsseldorf, Germany. Exhibiting in Hall 6, booth A10, Winner Medical will display...
PD-1/VEGF Bi-Specific Antibody (AK112) Obtained Approval to Initiate a Phase II Clinical Trial for Monotherapy or Combined Chemotherapy Neoadjuvant/Adjuvant Therapy of Resectable Non-Small Cell Lung Cancer
HONG KONG, Nov. 2, 2021 /PRNewswire/ -- Akeso, Inc. (the Company, 9926.HK) announces that AK112 (PD-1/VEGF bi-specific antibody), the novel immuno-oncology drug independently developed by the Company, obtained approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration of the People's Republic of China to initiate a phase II clinical trial for monotherapy or...
New discovery: Banana beats insomnia and anti-anxiety, approved by the US FDA
TAIPEI, Nov. 2, 2021 /PRNewswire/ -- TCI Co., Ltd. has long been engaged in the research and development of banana peels and banana stamens, and finally passed the US FDA NDI approval in the middle of this year, becoming the world's first banana NDI. It is an important milestone for Taiwan's banana products to enter the world, and it...
Antengene Granted IND Approval in China for the Phase Ib Study of ATG-008 (Onatasertib) in Combination with ATG-010 (Selinexor) in Patients with Diffuse Large B-Cell Lymphoma
SHANGHAI and HONG KONG, Nov. 2, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that China's National Medical Products Administration (NMPA) has approved an open-label Phase Ib dose-escalation study...
Carcell Biopharma closes an oversubscribed financing round led by Hyfinity Investments
SINGAPORE, Nov. 2, 2021 /PRNewswire/ -- Carcell Biopharma ("Carcell", the "Company") announced today the close of an over-subscribed financing. The round was led by Hyfinity Investments, with participation from BioTrack Capital, Legendstar Capital and other investors. Carcell Biopharma is a pre-clinical biotech company incubated by EVX Ventures. Following a "platform of platforms"...
TurtleTree Raises US$30 Million in First Tranche of Series A Funding
SAN FRANCISCO, Calif., and SINGAPORE, Nov. 1, 2021 /PRNewswire/ -- TurtleTree has successfully raised US$30 million in the first tranche of their Series A funding, one of the largest investment rounds to date in Asia's cell-based food sector. Rapidly gaining prominence for its novel use of cell-based technology in milk production, the biotech company has now secured fresh funding from...
SOPHiA GENETICS Launches SOPHiA DDM™ for SureSelect Human All Exon v8
New bioinformatic workflow advances analysis capabilities for whole exome assessment and interpretation BOSTON and LAUSANNE, Switzerland, Nov. 1, 2021 /PRNewswire/ -- SOPHiA GENETICS SA (Nasdaq: SOPH), the creator of a global data pooling and knowledge sharing platform that advances data-driven medicine, announced today they have extended their SOPHiA DDM™ Universal Whole Exome analytical capabilities to include industry...
